'The Twenty-Seven Pages’ was hardly going to be an essay in...

'The Twenty-Seven Pages’ was hardly going to be an essay in praise of the new strategy, and would have caused BOD members to wriggle.

BOD: You’re right, our new strategy is full of flaws, and we wish you’d been here. How can we fix this mess?
Dr T: Now that we’re finally on the same page, I suggest we do the following...

Spare a thought for the egg-on-face that genuinely smart people have copped, yet they’ve had the integrity to put facts and arguments ahead of face-saving and bluster (and no doubt the shareholding structure was also persuasive). Dr T is probably right, but he needs team support and validation, and of course isn't infallible - eg, expecting a new SOC for EMD/AMD as a trial precondition was clearly in hindsight a step too far.

'Out-of-the-box’ bisantrene entails an out-of-the-box response, and I’m cautiously hopeful the right ingredients may now have come together.